IQVIA Holdings: Positioned for Growth with Strategic Innovations and Industry Recovery
TipRanks (Wed, 17-Dec 1:55 PM ET)
TipRanks (Wed, 17-Dec 7:20 AM ET)
Bank of America Securities Sticks to Their Buy Rating for IQVIA Holdings (IQV)
TipRanks (Mon, 15-Dec 7:25 AM ET)
Barclays Keeps Their Hold Rating on IQVIA Holdings (IQV)
TipRanks (Mon, 15-Dec 4:26 AM ET)
Business Wire (Tue, 2-Dec 8:00 AM ET)
NEXT Oncology Expands to Japan in Joint Venture Partnership With Kansai Medical University
Business Wire (Wed, 5-Nov 9:00 AM ET)
IQVIA Reports Third-Quarter 2025 Results
Business Wire (Tue, 28-Oct 7:00 AM ET)
IQVIA CEO Ari Bousbib to Speak at UBS Global Healthcare Conference on November 11, 2025
Business Wire (Tue, 21-Oct 4:15 PM ET)
IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025
Business Wire (Tue, 30-Sep 4:15 PM ET)
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Iqvia Hldgs trades on the NYSE stock market under the symbol IQV.
As of December 19, 2025, IQV stock price declined to $220.69 with 4,027,673 million shares trading.
IQV has a beta of 0.84, meaning it tends to be less sensitive to market movements. IQV has a correlation of 0.15 to the broad based SPY ETF.
IQV has a market cap of $37.58 billion. This is considered a Large Cap stock.
Last quarter Iqvia Hldgs reported $4 billion in Revenue and $3.00 earnings per share. This beat revenue expectation by $26 million and exceeded earnings estimates by $.14.
In the last 3 years, IQV traded as high as $261.73 and as low as $134.65.
The top ETF exchange traded funds that IQV belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
IQV has underperformed the market in the last year with a price return of +15.6% while the SPY ETF gained +17.3%. However, in the short term, IQV had mixed performance relative to the market. It has outperformed in the last 3 months, returning +16.0% vs +3.3% return in SPY. But in the last 2 weeks, IQV shares have been beat by the market, returning -1.9% compared to an SPY return of -0.6%.
IQV support price is $218.39 and resistance is $226.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IQV shares will trade within this expected range on the day.